Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.
Shanghai Fosun Pharmaceutical has released its unaudited third quarterly report for 2024, detailing the company’s financial performance for the three months ending September 30. The report adheres to the PRC Accounting Standards for Business Enterprises, ensuring transparency and reliability for investors. This update provides crucial insights for stakeholders monitoring the company’s financial health and market position.
For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.
